Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Supernus Pharmaceuticals, Inc. on June 15, 2020. The filing details the vote tabulation for five proposals submitted to security holders. As of the record date (April 16, 2020), there were 52,537,659 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity. Investors should refer to the Company's Form 10-K or 10-Q for financial performance metrics.
Material Changes and Voting Results
The filing documents the successful passage of all five proposals at the Annual Meeting:
- Proposal 1 (Election of Class II Directors): Both Frederick M. Hudson and Charles W. Newhall, III were elected. Significant broker non-votes (4,642,150) were recorded for this proposal.
- Proposal 2 (Ratification of Auditors): KPMG LLP was ratified as the independent public accounting firm with 47,089,148 votes for and only 26,239 against.
- Proposal 3 (Executive Compensation): The non-binding advisory vote on executive compensation passed with 41,452,065 votes for and 1,033,892 against.
- Proposal 4 (Equity Incentive Plan Amendment): Stockholders approved the amendment to increase available shares under the 2012 Equity Incentive Plan (41,041,549 for vs. 1,449,817 against).
- Proposal 5 (Employee Stock Purchase Plan Amendment): Stockholders approved the amendment to increase available shares and make technical changes to the 2012 Employee Stock Purchase Plan (42,433,004 for vs. 82,973 against).
Guidance, Outlook, and Risks
This document contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a disclosure of shareholder voting outcomes.
Important Facts for Investors to Verify
- Verify the specific number of shares authorized for issuance under the amended Equity Incentive Plan and Employee Stock Purchase Plan in the definitive proxy statement filed on April 24, 2020.
- Note the high volume of broker non-votes (4,642,150) on the director election and equity plan proposals, indicating shares held in street name where brokers lacked discretionary voting power.
- Confirm the tenure of the newly elected Class II Directors, who will serve until the 2023 Annual Meeting.